Hagerstown, MDNCT07235085Now EnrollingIRB Ready

Non-Proliferative Diabetic Retinopathy Clinical Trial in Hagerstown, MD

Access cutting-edge non-proliferative diabetic retinopathy treatment through this phase 3 clinical trial at a research site in Hagerstown. Study-provided care at no cost to qualified participants.

Sponsored by Ocular Therapeutix, Inc.

Quick Self-Assessment

See if you qualify for this Hagerstown location

Preparing your pre-screening questions…

Expert Care in Hagerstown

Access non-proliferative diabetic retinopathy specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related non-proliferative diabetic retinopathy treatment provided free

Apply for This Hagerstown Location

Check if you qualify for this non-proliferative diabetic retinopathy clinical trial in Hagerstown, MD

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Hagerstown

    Convenient for MD residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Hagerstown site if eligible
  4. 4Begin participation

About This Non-Proliferative Diabetic Retinopathy Study in Hagerstown

The purpose of this trial is to study the safety and effectiveness of OTX-TKI (axitinib intravitreal hydrogel) for the treatment of Non-Proliferative Diabetic Retinopathy. OTX-TKI is an intravitreal hydrogel embedded with axitinib. When the OTX-TKI hydrogel is administered into the vitreous cavity of the eye, the hydrogel begins to slowly break down, which allows the axitinib to be slowly released over time. This clinical trial is comparing OTX-TKI to a "sham" injection procedure. The sham injection is a mock injection procedure, but nothing will actually be inserted in the eye as there is no needle on the sham injector. Only one eye ("study eye") will be treated with study treatment.

Sponsor: Ocular Therapeutix, Inc.

Who Can Participate

Inclusion Criteria

Male or female who is at least 18 years of age at the time of signing the informed consent form (ICF)
History of or newly diagnosed with type 1 or 2 diabetes mellitus and have moderately severe to severe NPDR (DRSS levels 47 or 53), confirmed by the Central Reading Center (CRC) based on the images obtained at the Screening visit
BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of ≥ 69 letters (approximate Snellen equivalent of 20/40 or better) in the study eye
Willing and able to comply with clinic visits and study-related procedures
Provide signed informed consent

Exclusion Criteria

Presence of center-involved diabetic macular edema (CI-DME) defined per protocol via optical coherence tomography (SD-OCT) in the study eye, obtained at the Screening visit
Evidence of a rhegmatogenous retinal detachment or visually significant/severe epiretinal membrane, vitreomacular traction syndrome, macular hole, tear of the retinal pigment epithelium in the macula, or other macular pathology in the study eye deemed visually significant by the Investigator
In the study eye, any panretinal photocoagulation (PRP) treatment prior to baseline, or received focal or grid laser photocoagulation within 1000 microns of the central subfield of the macula within 6 months prior to baseline
IVT anti-VEGF treatment in the study eye within 6 months or port delivery system (PDS) with ranibizumab in the study eye at any time prior to baseline (Day 1)
(There are additional exclusion criteria)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Hagerstown?

Yes, this clinical trial (NCT07235085) has an active research site in Hagerstown, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Non-Proliferative Diabetic Retinopathy Treatment Options in Hagerstown, MD

If you're searching for non-proliferative diabetic retinopathy treatment options in Hagerstown, MD, this clinical trial (NCT07235085) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Hagerstown research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced non-proliferative diabetic retinopathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all non-proliferative diabetic retinopathy clinical trials near you to find additional studies recruiting in your area.

More Essential Tremor Trials in Hagerstown, MD

See all essential tremor clinical trials recruiting in Hagerstown — not just this study.

Browse Essential Tremor Trials in Hagerstown →

Browse More Trials by Condition

Essential Tremor TrialsRheumatoid Arthritis TrialsType 2 Diabetes TrialsInterstitial Cystitis TrialsDiabetic Retinopathy TrialsAll Conditions →

Ready to Join in Hagerstown?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Hagerstown, MD